查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102761

生物標記檢測服務市場：全球市場預測，2026-2032年

Biomarker Testing Services Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物標記檢測服務市場將成長至 19 億美元，複合年成長率為 7.64%。

主要市場統計數據
基準年 2025 11.3億美元
預計年份：2026年 12.1億美元
預測年份 2032 19億美元
複合年成長率 (%) 7.64%

生物標記檢測服務執行摘要

生物標記檢測服務對於實現精準醫療至關重要，它能夠支持疾病風險評估、早期發現、診斷、預後、治療方案選擇、治療進展監測以及復發檢測。這項需求源自於基因體學、蛋白質體學、循環系統、感染疾病遺傳學和免疫學生物標記物在腫瘤學、心臟病學、代謝體學、自體免疫疾病和罕見疾病等領域日益廣泛的臨床應用。在腫瘤學領域，檢驗的生物標記檢測正日益被納入臨床路徑，作為標靶治療治療和免疫治療的指南；而在慢性病管理中，生物標記組合則有助於臨床醫生對患者進行分層並提供個性化干預。

生物標記檢測領域的變革性變化

生物標記檢測服務產業正經歷一場變革性的轉變，從單一分析測試轉向整合的多組體學和全面分析。臨床檢查室、醫院網路、大學附屬醫院和專科檢測機構正擴大採用高通量平台，這些平台可以並行評估DNA、RNA、蛋白質、代謝物和免疫特徵。這種轉變使得診斷更加精準，患者分層更加細緻，尤其是在癌症治療、遺傳性疾病和複雜性慢性疾病領域。

人工智慧對生物標記檢測的累積影響

人工智慧正透過提升數據解讀、工作流程效率和臨床決策支持，對整個生物標記檢測服務產生累積影響。機器學習模型正被擴大用於檢測基因組序列、數位病理影像、放射組學資料集、蛋白質組學譜和縱向臨床記錄中的複雜生物標記模式。在經過檢驗的臨床和法律規範內，這些工具可以幫助對突變進行分類、評估腫瘤微環境、對患者進行分層、預測治療反應並識別不利事件風險。

關於生物標記檢測服務的關鍵區域見解

在亞太地區，由於癌症篩檢計畫的擴展、基因組醫學計畫的增加、慢性病負擔的加重以及檢查室的投入，生物標記檢測服務正迅速發展。中國、日本、韓國、印度、澳洲和一些東南亞國家正透過國家級基因組舉措、醫院分子診斷和臨床試驗活動來加強其精準醫療能力。在北美，生物標記檢測得到了完善的臨床指南、先進分子診斷技術的廣泛應用、癌症臨床試驗的高參與率、成熟的檢查室認證體係以及針對特定伴隨診斷和基因組檢測的保險報銷機制的支持。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協，隨著成員國在腫瘤學、感染疾病控制、生殖醫學和孕產婦保健領域擴大分子診斷的應用，東協正崛起為生物標記檢測服務的重要市場。由於醫療保健資金、檢查室認證和專家資源等方面的差異，新加坡、泰國、馬來西亞、印尼、越南和菲律賓的發展進程不盡相同。在海灣合作理事會（GCC）國家，基因組醫學、婚前和新生兒篩檢、腫瘤檢測以及數位醫療基礎設施是優先事項，而對精準醫療的政策支持和對本地檢測能力的加強正在推動對高品質生物標記檢測服務的需求。

主要國家生物標記檢測服務的發展趨勢

美國仍然是生物標記檢測服務領域最先進的國家之一，這得益於其與臨床指南的整合、分子病理學方面的專業知識、伴隨診斷的引入、檢查室自建檢測（LDT）的開展以及廣泛的臨床研究參與。加拿大透過其省級醫療保健系統和癌症計畫持續擴大基因組檢測的覆蓋範圍，而墨西哥則透過私人實驗室、癌症中心和傳染病檢查系統來擴大檢測的可及性。巴西是拉丁美洲最大的精準診斷中心，在腫瘤學、生殖醫學和感染疾病領域的需求不斷成長。

為生物標記檢測領域的領導者提供的實用建議

產業領導者應優先考慮符合治療指南、伴隨診斷要求和真實世界證據預期的、具有臨床實用價值的生物標記檢測組合。建構涵蓋次世代定序、液態生物檢體、免疫組織化學、聚合酵素鏈鎖反應(PCR)、流式細胞技術、質譜和多體學分析等方面的能力，可以提升腫瘤學、罕見疾病、心血管代謝疾病、感染疾病和神經病學等領域的服務效用。醫療機構還應投資於檢查室認證、外部品質評估、檢驗的生物資訊流程、能力驗證和標準化報告，以增強臨床醫生的信心並獲得保險公司的認可。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，重點在於與生物標記檢測服務相關的檢驗且基於證據的資料資訊來源。該調查方法包括對公開的臨床指南、監管文件、同行評審的科學文獻、公共衛生出版物、檢查室標準、報銷政策參考資料、精準醫療計畫文件以及疾病特異性檢測建議的出版刊物。尤其注重由衛生當局、標準化機構、臨床學會和學術研究資訊來源等可靠來源所支持的資料點和趨勢。

結論

隨著醫療保健系統越來越依賴經過驗證的分子和細胞指標來提高診斷準確性、最佳化治療方案製定、監測檢驗並支持臨床研究，生物標記檢測服務在精準醫療中變得至關重要。在擁有先進檢測基礎設施、完善的報銷體系、臨床指南和可互通數據系統的地區，生物標記檢測的發展勢頭最為強勁。然而，不同地區在可近性、成本挑戰、監管複雜性、人員短缺和證據要求等方面的差異，仍影響著生物標記檢測服務的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物標記檢測服務市場：依服務類型分類

  • 分析測試服務
  • 臨床實驗室服務
  • 客製化和合約服務
  • 監理和合規服務

第8章：生物標記檢測服務市場：依技術分類

  • 生物資訊學和數據平台
  • 基於細胞的檢測
  • 分子技術
    • 原位雜合反應
      • 顯色原位雜合反應（CISH）
      • 基於螢光的雜合反應（FISH）
    • 微陣列
    • 次世代定序（NGS）
    • 聚合酵素鏈鎖反應（PCR）
      • 數位PCR
      • 定量聚合酵素鏈鎖反應（qPCR）
  • 基於蛋白質的技術
    • 流式細胞技術
    • 免疫測量
      • 酵素免疫分析法（ELISA）
      • 西方墨點法
    • 質譜分析
      • LC-MS/MS
      • MALDI-TOF

第9章：生物標記檢測服務市場：依應用領域分類

  • 伴隨診斷
    • 腫瘤學
    • 個人化醫療
  • 疾病診斷
    • 心血管系統
    • 感染疾病
    • 腫瘤學
  • 藥物研發
    • 臨床試驗
    • 藥物發現
    • 毒理學

第10章：生物標記檢測服務市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 醫院和診斷檢測實驗室
  • 製藥和生物技術公司

第11章：生物標記檢測服務市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：生物標記檢測服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：生物標記檢測服務市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Agilent Technologies, Inc.
  • Avid Bioservices, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs
  • BiomarkerBay BV
  • Bristol Myers Squibb
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Icon PLC
  • Intertek Group PLC
  • IQVIA Holdings, Inc.
  • JSR Life Sciences, LLC
  • KCAS Group
  • Laboratory Corporation of America Holdings
  • LGC Group
  • Merck KGaA
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Parexel International Corporation
  • PerkinElmer Inc.
  • Randox Laboratories
  • SGS SA
  • Shuwen Biotech Co., Ltd.
  • Syneos Health
  • Thermo Fisher Scientific, Inc.
  • WuXi Biologics Inc.
Product Code: MRR-B16853779DF0

The Biomarker Testing Services Market is projected to grow by USD 1.90 billion at a CAGR of 7.64% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.13 billion
Estimated Year [2026] USD 1.21 billion
Forecast Year [2032] USD 1.90 billion
CAGR (%) 7.64%

Biomarker Testing Services Executive Summary

Biomarker testing services have become a critical enabler of precision medicine, supporting disease risk assessment, early detection, diagnosis, prognosis, therapy selection, treatment monitoring, and recurrence surveillance. Demand is being shaped by the growing clinical use of genomic, proteomic, metabolomic, epigenetic, and immunologic biomarkers across oncology, cardiology, neurology, infectious diseases, autoimmune disorders, and rare diseases. In oncology, validated biomarker testing is increasingly embedded in clinical pathways to guide targeted therapies and immunotherapies, while in chronic disease management, biomarker panels are helping clinicians stratify patients and personalize interventions.

The sector is also benefiting from broader adoption of next-generation sequencing, polymerase chain reaction assays, immunoassays, mass spectrometry, flow cytometry, digital pathology, and liquid biopsy workflows. Regulatory emphasis on analytical validity, clinical validity, clinical utility, laboratory quality systems, and companion diagnostic alignment is raising the bar for service providers. As healthcare systems shift from generalized treatment to evidence-led precision care, biomarker testing services are becoming central to clinical decision-making, clinical trial design, drug development, and population health strategies.

Transformative Shifts in the Biomarker Testing Landscape

The biomarker testing services landscape is undergoing transformative change as testing moves from single-analyte assays toward integrated multi-omics and comprehensive profiling. Clinical laboratories, hospital networks, academic medical centers, and specialized testing providers are increasingly adopting high-throughput platforms that can evaluate DNA, RNA, proteins, metabolites, and immune signatures in parallel. This shift is improving diagnostic resolution and enabling more refined patient stratification, particularly in cancer care, inherited disorders, and complex chronic diseases.

Another major shift is the rise of decentralized and digitally connected testing models. Point-of-care technologies, remote sample collection, electronic ordering, and cloud-enabled laboratory information systems are improving access while reducing turnaround time. At the same time, payers and health technology assessment bodies are placing greater scrutiny on clinical utility, reimbursement evidence, and real-world outcomes. Service providers that can demonstrate quality, interoperability, rapid reporting, and clear clinical actionability are better positioned in an environment where healthcare systems are prioritizing value-based care, guideline adherence, and measurable patient benefit.

Cumulative Impact of Artificial Intelligence on Biomarker Testing

Artificial intelligence is creating cumulative impact across biomarker testing services by improving data interpretation, workflow efficiency, and clinical decision support. Machine learning models are increasingly used to detect complex biomarker patterns in genomic sequences, digital pathology images, radiomics datasets, proteomic profiles, and longitudinal clinical records. These tools can support variant classification, tumor microenvironment assessment, patient stratification, therapy response prediction, and adverse event risk identification when used within validated clinical and regulatory frameworks.

AI is also improving laboratory operations through automated quality control, sample tracking, anomaly detection, and report generation. Natural language processing can help extract clinically relevant information from pathology reports, electronic health records, and research datasets, enabling more complete biomarker interpretation. However, adoption of AI in biomarker testing requires transparent model validation, bias monitoring, cybersecurity controls, data governance, and clinician oversight. Organizations that integrate AI responsibly can enhance diagnostic confidence, reduce turnaround times, and support more scalable precision medicine services without compromising clinical safety.

Key Regional Insights for Biomarker Testing Services

Asia-Pacific is advancing rapidly in biomarker testing services due to expanding cancer screening initiatives, increasing genomic medicine programs, rising chronic disease burden, and investments in laboratory infrastructure. China, Japan, South Korea, India, Australia, and several Southeast Asian countries are strengthening precision medicine capabilities through national genomics initiatives, hospital-based molecular diagnostics, and clinical trial activity. In North America, biomarker testing is supported by established clinical guidelines, broad availability of advanced molecular diagnostics, high participation in oncology trials, mature laboratory accreditation systems, and reimbursement pathways for selected companion diagnostics and genomic tests.

Latin America is showing steady adoption, led by Brazil and Mexico, where oncology diagnostics, infectious disease testing, and private-sector laboratory networks are expanding access, although reimbursement variability and uneven infrastructure remain constraints. Europe benefits from strong regulatory oversight, cross-border research collaboration, and public health systems that increasingly incorporate molecular diagnostics into cancer and rare disease care, while the regional regulatory environment emphasizes quality, evidence generation, and data protection. The Middle East is investing in precision medicine, genomic screening, and specialized diagnostic centers, particularly in higher-income Gulf economies seeking to reduce reliance on overseas testing. Africa remains at an earlier stage of biomarker testing adoption, with progress linked to infectious disease diagnostics, oncology capacity building, public health partnerships, and gradual expansion of molecular laboratory networks, though affordability, workforce availability, and sample logistics continue to influence access.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is emerging as an important biomarker testing services environment as member states expand molecular diagnostics in oncology, infectious disease management, reproductive health, and maternal health, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines progressing at different speeds due to differences in healthcare funding, laboratory accreditation, and specialist availability. The GCC is prioritizing genomic medicine, premarital and newborn screening, oncology testing, and digital health infrastructure, with policy support for precision medicine and localized laboratory capacity strengthening demand for high-quality biomarker testing services.

The European Union provides a highly structured setting for biomarker testing, shaped by harmonized medical device regulation, strong data protection requirements, collaborative cancer initiatives, rare disease networks, and public research funding. BRICS countries represent a diverse growth environment: China and India are scaling molecular diagnostics and genomics capacity; Brazil is expanding oncology and infectious disease testing; Russia maintains capabilities in clinical diagnostics and biomedical research; and South Africa plays a strategic role in infectious disease biomarker research and regional laboratory capacity. The G7 group is characterized by advanced research ecosystems, established regulatory systems, precision oncology adoption, and significant clinical trial infrastructure, while NATO countries collectively benefit from strong health security priorities, biodefense-related diagnostics, interoperable data initiatives, and investments in resilient laboratory systems.

Key Country Insights for Biomarker Testing Services

The United States remains one of the most advanced biomarker testing service environments, supported by clinical guideline integration, molecular pathology expertise, companion diagnostic adoption, laboratory-developed test activity, and extensive clinical research participation. Canada continues to expand genomic testing through provincial healthcare systems and cancer programs, while Mexico is increasing access through private laboratories, oncology centers, and infectious disease testing capacity. Brazil is the largest precision diagnostics hub in Latin America, with growing demand in oncology, reproductive health, and infectious disease applications.

In Europe, the United Kingdom is advancing genomics-enabled healthcare through national sequencing programs and cancer diagnostics modernization. Germany combines strong laboratory medicine infrastructure, advanced pathology capabilities, and broad clinical research activity. France is strengthening molecular testing through national oncology and rare disease frameworks, while Italy and Spain are expanding biomarker use in cancer care and hospital-based diagnostics. Russia maintains domestic diagnostic capacity and biomedical research activity, although access, reimbursement, and integration vary across regions.

In Asia-Pacific, China is scaling biomarker testing through cancer genomics, liquid biopsy research, reproductive genetics, and expanding hospital laboratory networks. India is seeing increased use of molecular diagnostics in oncology, infectious disease testing, and hereditary disease assessment, supported by a growing private diagnostics sector and rising clinician awareness. Japan has well-established precision medicine adoption, particularly in oncology, supported by regulatory pathways for companion diagnostics and national health coverage mechanisms for selected genomic tests. Australia benefits from strong clinical genomics programs, cancer research networks, and population-scale precision health initiatives. South Korea is advancing through high digital health readiness, sophisticated hospital systems, cancer genomic profiling, and national interest in data-driven healthcare.

Actionable Recommendations for Biomarker Testing Leaders

Industry leaders should prioritize clinically actionable biomarker testing portfolios aligned with treatment guidelines, companion diagnostic requirements, and real-world evidence expectations. Building capabilities across next-generation sequencing, liquid biopsy, immunohistochemistry, polymerase chain reaction, flow cytometry, mass spectrometry, and multi-omics analytics can improve service relevance across oncology, rare diseases, cardiometabolic conditions, infectious diseases, and neurology. Providers should also invest in laboratory accreditation, external quality assessment, validated bioinformatics pipelines, proficiency testing, and standardized reporting to strengthen clinician confidence and payer acceptance.

Strategic priorities include reducing turnaround time, improving sample logistics, expanding access beyond major urban centers, and integrating biomarker results into electronic health records and clinical decision support systems. Organizations should establish partnerships with hospitals, academic centers, drug developers, and public health agencies to support clinical trials, companion diagnostic development, and population screening programs. AI adoption should be governed by transparent validation, human oversight, cybersecurity, and bias mitigation. Leaders that demonstrate clinical utility, operational reliability, data interoperability, and ethical data governance will be best positioned to support sustainable precision medicine adoption.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, evidence-based sources relevant to biomarker testing services. The methodology includes review of publicly available clinical guidelines, regulatory documents, peer-reviewed scientific literature, public health agency publications, laboratory standards, reimbursement policy references, precision medicine program documentation, and disease-specific testing recommendations. Emphasis is placed on data points and trends supported by credible institutions, including health authorities, standards organizations, clinical societies, and academic research sources.

The analysis evaluates biomarker testing across technology platforms, clinical applications, regulatory considerations, regional adoption patterns, and healthcare system readiness. Insights are synthesized through qualitative triangulation to ensure consistency across multiple authoritative sources. The scope excludes market estimation, market sizing, market share assessment, and forecasting. The objective is to provide decision-makers with a practical, evidence-led view of industry dynamics, adoption drivers, barriers, and strategic priorities in biomarker testing services.

Conclusion

Biomarker testing services are becoming indispensable to precision medicine as healthcare systems increasingly rely on validated molecular and cellular indicators to improve diagnosis, guide therapy, monitor response, and support clinical research. The strongest momentum is occurring where advanced laboratory infrastructure, reimbursement alignment, clinical guidelines, and interoperable data systems converge. At the same time, uneven access, affordability challenges, regulatory complexity, workforce limitations, and evidence requirements continue to shape adoption across regions.

The next phase of biomarker testing will be defined by multi-omics integration, liquid biopsy expansion, AI-enabled interpretation, decentralized access models, and stronger links between laboratory results and clinical decision support. Service providers that combine scientific rigor, operational excellence, regulatory compliance, data protection, and demonstrable clinical utility will play a central role in advancing personalized healthcare and improving patient outcomes across global markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biomarker Testing Services Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Testing Services
  • 7.3. Clinical Testing Services
  • 7.4. Custom & Contract Services
  • 7.5. Regulatory & Compliance Services

8. Biomarker Testing Services Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics & Data Platforms
  • 8.3. Cell-Based Assays
  • 8.4. Molecular Technologies
    • 8.4.1. In Situ Hybridization
      • 8.4.1.1. Chromogenic In Situ Hybridization (CISH)
      • 8.4.1.2. Fluorescence In Situ Hybridization (FISH)
    • 8.4.2. Microarrays
    • 8.4.3. Next-Generation Sequencing (NGS)
    • 8.4.4. Polymerase Chain Reaction (PCR)
      • 8.4.4.1. Digital PCR
      • 8.4.4.2. Quantitative Polymerase Chain Reaction (qPCR)
  • 8.5. Protein-Based Technologies
    • 8.5.1. Flow Cytometry
    • 8.5.2. Immunoassays
      • 8.5.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 8.5.2.2. Western Blot
    • 8.5.3. Mass Spectrometry
      • 8.5.3.1. LC-MS/MS
      • 8.5.3.2. MALDI-TOF

9. Biomarker Testing Services Market, by Application

  • 9.1. Introduction
  • 9.2. Companion Diagnostics
    • 9.2.1. Oncology
    • 9.2.2. Personalized Medicine
  • 9.3. Disease Diagnosis
    • 9.3.1. Cardiovascular
    • 9.3.2. Infectious Disease
    • 9.3.3. Oncology
  • 9.4. Drug Development
    • 9.4.1. Clinical Trials
    • 9.4.2. Discovery
    • 9.4.3. Toxicology

10. Biomarker Testing Services Market, by End User

  • 10.1. Introduction
  • 10.2. Academic And Research Institutes
  • 10.3. Contract Research Organizations
  • 10.4. Hospitals And Diagnostics Labs
  • 10.5. Pharmaceutical And Biotechnology Companies

11. Biomarker Testing Services Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Biomarker Testing Services Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Biomarker Testing Services Market, by Country

  • 13.1. United States
  • 13.2. Germany
  • 13.3. China
  • 13.4. United Kingdom
  • 13.5. India
  • 13.6. Japan
  • 13.7. Russia
  • 13.8. Brazil
  • 13.9. Canada
  • 13.10. Italy
  • 13.11. Mexico
  • 13.12. France
  • 13.13. Spain
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Agilent Technologies, Inc.
  • 15.2. Avid Bioservices, Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. BioAgilytix Labs
  • 15.5. BiomarkerBay B. V.
  • 15.6. Bristol Myers Squibb
  • 15.7. Eurofins Scientific SE
  • 15.8. F. Hoffmann-La Roche AG
  • 15.9. Icon PLC
  • 15.10. Intertek Group PLC
  • 15.11. IQVIA Holdings, Inc.
  • 15.12. JSR Life Sciences, LLC
  • 15.13. KCAS Group
  • 15.14. Laboratory Corporation of America Holdings
  • 15.15. LGC Group
  • 15.16. Merck KGaA
  • 15.17. Myriad Genetics, Inc.
  • 15.18. NeoGenomics Laboratories
  • 15.19. Parexel International Corporation
  • 15.20. PerkinElmer Inc.
  • 15.21. Randox Laboratories
  • 15.22. SGS S.A.
  • 15.23. Shuwen Biotech Co., Ltd.
  • 15.24. Syneos Health
  • 15.25. Thermo Fisher Scientific, Inc.
  • 15.26. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOMARKER TESTING SERVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOMARKER TESTING SERVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOMARKER TESTING SERVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOMARKER TESTING SERVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOMARKER TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL BIOMARKER TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOMARKER TESTING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CUSTOM & CONTRACT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CUSTOM & CONTRACT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CUSTOM & CONTRACT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REGULATORY & COMPLIANCE SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REGULATORY & COMPLIANCE SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL REGULATORY & COMPLIANCE SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOINFORMATICS & DATA PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOINFORMATICS & DATA PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOINFORMATICS & DATA PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROTEIN-BASED TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROTEIN-BASED TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROTEIN-BASED TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WESTERN BLOT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL WESTERN BLOT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL WESTERN BLOT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LC-MS/MS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LC-MS/MS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LC-MS/MS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALDI-TOF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MALDI-TOF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALDI-TOF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DISEASE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DISEASE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DISEASE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TOXICOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TOXICOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TOXICOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS AND DIAGNOSTICS LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS AND DIAGNOSTICS LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS AND DIAGNOSTICS LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 227. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 269. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 283. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 285. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 290. NATO BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 326. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2032 (US